Cardiac surgery

excellent solutions for cardiac surgery

Cardiac surgery

Surgeons within cardiac use the Vivostat® System for many different surgical procedures – and they have done so for more than two decades. Trusted by cardiac surgeons throughout Europe, Vivostat® proves invaluable in a variety of critical procedures.

surgical applications in cardiac surgery

  • Coronary artery bypass grafting (CABG)
  • Aortic constructions
  • Congenital heart surgery
  • Implantation of vascular prostheses
  • Operation for active endocarditis of the aortic root
  • Type A aortic dissection
  • Deep sternal wounds 
  • LVAD (left ventricular assist device) procedures
  • Surgery in high-risk patients, i.e. patients in anticoagulation therapy, plavix therapy and diabetic patients

While significant strides have been made in cardiac surgery, challenges persist. Vivostat® meet these challenges, offering solutions for:

  • Haemostasis of diffuse bleedings
  • Suture line sealing
  • Tissue regeneration
  • Infection control, treatment and prevention

main advantages using vivostat® in cardiac surgery

surgical applications in cardiac surgery

The Vivostat® Systems provides surgeons with a choice of two remarkable products to address these challenges effectively.

If haemostasis and/or sealing are the primary challenges, Vivostat® Fibrin is an excellent choice. When tissue regeneration is paramount, Vivostat® PRF stands as the optimal choice.

Vivostat® Fibrin: autologous fibrin outperforming other fibrin sealants in key parameters such as polymerization, elasticity, adhesion, and its impact on tissue.

Vivostat® PRF: a cutting-edge, second-generation platelet-enriched product, functioning as both a hemostat/sealant and a supportive agent for tissue regeneration and wound healing.


Vivostat® in cardiac surgery

Click on the video and see the Vivostat® System in use in cardiac surgery.

Unique application devices for cardiac surgery

As part of the Vivostat® System you also find a wide range of different application devices for minimal invasive and robotics in cardiac surgery. As an example, the Vivostat® Concorde spraypen is perfect for heart surgery, where the pre-bent tip allows the surgeon to reach difficult areas like the backside of the heart.

The spraypen is designed to deliver the sealant/matrix to the surgical site in a precise and targeted manner, without experiencing the blockage that is common in conventional sealant systems – in fact, the application devices in the Vivostat® System all allows for the surgeon to deliver the solution intermittently while also giving the opportunity to co-deliver medications like antibiotics and painkillers together with the solutions. No other system on the market allows this.

Vivostat® Co-Delivery

The revolutionary system makes it possible to co-apply e.g. stem cells or antibiotics with the Vivostat® product.

Vivostat® PRF

Using the Vivostat® System, you can prepare autologous platelets with multiple growth factors embedded in a matrix. 

Kjærgård, H. K., & Trumbull, H. R. (1998). Vivostat system autologous fibrin sealant: preliminary study in elective coronary bypass grafting. The Annals of Thoracic Surgery, 66(2), 482–486.

Kjaergard, H. K., & Trumbull, H. R. (2000), Bleeding from the sternal marrow can be stopped using Vivostat patient derived fibrin sealant, The Annals of Thoracic Surgery, 69(4), 1173–1175,

Hanks, J. B., Kjaergard, H. K., & Hollingsbee, D. (2003), A comparison of the haemostatic effect of Vivostat patient-derived fibrin sealant with oxidised cellulose (Surgicel) in multiple surgical procedures, European Surgical Research, 35(5), 439–444,

Franke, U., Albert, M., Rustenbach, C., & Baumbach, H. (2009). Minimally invasive Ross procedure through partial upper sternotomy. Interactive Cardiovascular and Thoracic Surgery, 9(3), 545–546.

Nardi, P. M., Ferraro, A., Scognamiglio, M., Viviano, A., Bellos, K., Lanti, A., Del Proposto, G., Pellegrino, A., Adorno, G., Isacchi, G., & Chiariello, L. (2010). The use of Topical Heamostatic Agents To Control Perioperative Bleeding In Cardiac Surgery, 57.

Van Wingerden, J. J., Coret, M. E., Van Nieuwenhoven, C. A., & Totté, E. (2010). The laparoscopically harvested omental flap for deep sternal wound infection. European Journal of Cardio-Thoracic Surgery, 37(1), 87–92.

Kuehnel, R. U., et al. (2011). Autologous Platelet Rich Fibrin PRF® using Growth Factors as a New Therapeutic Option for Sternal Wound Healing. Presented at World Society of Cardiothoracic Surgery.

Wiedemann, D., Vill, D., Bonaros, N., Laufer, G., Schachner, T., Kocher A. (2011), Topical use of autologous fibrin glue in high-risk CABG patients, European Surgery, 43(5), 309–314,

Kuehnel, R.-U., Michera, L., Loladze, G., Kuhn, Y., & Albes, J. (2012). The combination of vacuum therapy and Platelet Rich Fibrin – a new option in the treatment of mediastinitis. Presented at the Deutsche Gesellschaft für Wundheilung und Wundbehandlung congress.

Kühnel, R.U., Müller, T., Hartrumpf, M., Erb, M., Albes J.M. (2013), Application of platelet rich fibrin to prevent infection in the implantation of HeartWare®- LVAD-system, Kardiotechnik, 2, 43-45

Kuehnel, R.-U., Mueller, T., Romeike, L., Erb, M., & Albes, J. M. (2014). Application of platelet-rich fibrin for infection prophylaxis during implantation of HeartWare® LVAD systems.Immanuel Klinikum Bernau Herzzentrum Brandenburg, Abteilung für Herzchirurgie

Datta, S. (2016). Successful use of Platelet Rich Fibrin therapy (PRF) in post-operative cardiac surgical infected wounds: first reported case series. EACTS Daily News, Issue 2.

Foghsgaard, S., & Kjaergard, H. K. (n.d.). Important steps to avoid tamponade in minimally invasive aortic valve replacement